Literature DB >> 11999944

Advances in FDG PET probes in surgical oncology.

Richard Essner1, Farhad Daghighian, Armando E Giuliano.   

Abstract

Whole-body positron emission tomography (WB-PET) has been developed as a sensitive, cost-effective method for imaging malignant disease. WB-PET provides complete body imaging with a single scanning approach for a variety of malignancies. With increasing clinical experience, the indications for its use have broadened. This article reviews current uses of the technology and discusses some potential applications, particularly the utility of a commercially available surgical gamma probe for detecting the gamma particles emitted in the decay process of FDG.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11999944     DOI： 10.1097/00130404-200203000-00004

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  14 in total

1.  PET probes and oncological surgery: a productive new marriage for nuclear medicine?

Authors:  Orazio Schillaci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10       Impact factor: 9.236

2.  Comprehensive evaluation of occupational radiation exposure to intraoperative and perioperative personnel from 18F-FDG radioguided surgical procedures.

Authors:  Stephen P Povoski; Ismet Sarikaya; William C White; Steven G Marsh; Nathan C Hall; George H Hinkle; Edward W Martin; Michael V Knopp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-10       Impact factor: 9.236

3.  The use of intraoperative PET probe to resect metastatic melanoma.

Authors:  Grant O Lee; Nicholas G Costouros; Terry Groome; Mohammed Kashani-Sabet; Stanley P L Leong
Journal:  BMJ Case Rep       Date:  2010-07-15

Review 4.  A comprehensive overview of radioguided surgery using gamma detection probe technology.

Authors:  Stephen P Povoski; Ryan L Neff; Cathy M Mojzisik; David M O'Malley; George H Hinkle; Nathan C Hall; Douglas A Murrey; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2009-01-27       Impact factor: 2.754

5.  A hand-held beta imaging probe for FDG.

Authors:  Bipin Singh; Brendan C Stack; Samta Thacker; Valeriy Gaysinskiy; Twyla Bartel; Val Lowe; Steven Cool; Gerald Entine; Vivek Nagarkar
Journal:  Ann Nucl Med       Date:  2012-12-11       Impact factor: 2.668

6.  A novel method to localize antibody-targeted cancer deposits intraoperatively using handheld PET beta and gamma probes.

Authors:  Vivian E Strong; John Humm; Paul Russo; Achim Jungbluth; W Douglas Wong; Farhad Daghighian; Lloyd Old; Yuman Fong; Steven M Larson
Journal:  Surg Endosc       Date:  2007-11-20       Impact factor: 4.584

7.  Multimodal imaging and detection approach to 18F-FDG-directed surgery for patients with known or suspected malignancies: a comprehensive description of the specific methodology utilized in a single-institution cumulative retrospective experience.

Authors:  Stephen P Povoski; Nathan C Hall; Douglas A Murrey; Andrew Z Chow; Jay R Gaglani; Eamonn E Bahnson; Cathy M Mojzisik; Maureen P Kuhrt; Charles L Hitchcock; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2011-11-23       Impact factor: 2.754

8.  Intra-operative use of PET probe for localization of FDG avid lesions.

Authors:  M A Molina; W J Goodwin; F L Moffat; A N Serafini; G N Sfakianakis; E Avisar
Journal:  Cancer Imaging       Date:  2009-09-29       Impact factor: 3.909

9.  New applications of radioguided surgery in oncology.

Authors:  Almir Galvão Vieira Bitencourt; Eduardo Nóbrega Pereira Lima; Paula Nicole Vieira Pinto; Eduardo Bruno Lobato Martins; Rubens Chojniak
Journal:  Clinics (Sao Paulo)       Date:  2009-05       Impact factor: 2.365

10.  Combined approach of perioperative 18F-FDG PET/CT imaging and intraoperative 18F-FDG handheld gamma probe detection for tumor localization and verification of complete tumor resection in breast cancer.

Authors:  Nathan C Hall; Stephen P Povoski; Douglas A Murrey; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2007-12-21       Impact factor: 2.754
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.